Skip to content
Medical Health Aged Care

Dementia Australia welcomes new appointment of Age Discrimination Commissioner

Dementia Australia 2 mins read

Dementia Australia welcomes the appointment of Mr Robert Fitzgerald AM as the next Age Discrimination Commissioner.

 

The Age Discrimination Commissioner, operating within the Australian Human Rights Commission, leads the work to prevent age-based discrimination and promote equality across areas of employment, education, accommodation and the provision of goods and services.

 

In this position, Mr Fitzgerald will spearhead initiatives to combat age related disparities and to advocate for the rights of older people in Australia.

 

Mr Fitzgerald contributed to the Dementia-Friendly Communities Roundtable in NSW Parliament in September 2022 which resulted in the inaugural NSW Parliamentary Friends of Dementia Action Plan 2023-2025 released in September 2023.

 

Dementia Australia Executive Director, Services, Advocacy and Research Dr Kaele Stokes said the appointment was well deserved.

 

“Mr Fitzgerald has long championed the rights of older people, including those with a cognitive impairment, and this new appointment acknowledges his commitment to serving this community,” Dr Stokes said.

 

“In 2024 there are more than 421,000 people living with all forms of dementia in Australia. Without a medical breakthrough, the number of people is expected to increase to more than 812,500 by 2054.

 

“Older people living with dementia are more susceptible to elder abuse, including physical, emotional, psychological, sexual, social and financial abuse as well as neglect.

 

“Dementia Australia looks forward to working with Mr Fitzgerald to protect older Australians, especially people living with dementia or cognitive impairment who are more vulnerable within the community.”

 

Dementia Australia is the source of trusted information, education and services for the estimated more than 421,000 Australians living with dementia, and the more than 1.6 million people involved in their care. We advocate for positive change and support vital research. We are here to support people impacted by dementia, and to enable them to live as well as possible. No matter how you are impacted by dementia or who you are, we are here for you.

For support, please contact the National Dementia Helpline on 1800 100 500. An interpreter service is available. The National Dementia Helpline is funded by the Australian Government. People looking for information can also visit dementia.org.au

-Ends-

When talking or writing about dementia please refer to Dementia-Friendly Language Guidelines.

Media contacts: Sally Grandy, Senior Media and Communications Advisor, 0401 566710, [email protected]

Note to Editors:

We request, where possible, details for the National Dementia Helpline 1800 100 500 appear alongside news stories about dementia, as these stories often prompt questions or concerns:

If this story has prompted any questions or concerns, please call the National Dementia Helpline 1800 100 500 (24 hours, 7 days a week) or visit dementia.org.au.


Contact details:

Sally Grandy, Senior Media and Communications Advisor - 0401 566710

More from this category

  • Medical Health Aged Care
  • 17/12/2025
  • 13:11
GE HealthCare

GE HealthCare and Indonesia’s Ministry of Health to expand access to quality care through the provision of 300+ advanced CT scanners

300+ advanced CT scanners to be installed in public hospitals across 38 provinces by 2028, to support early diagnosis and treatment of non-communicable diseases.…

  • Contains:
  • Finance Investment, Medical Health Aged Care
  • 17/12/2025
  • 12:03
Jane Morgan Management

LTR Pharma surpasses 1,000 SPONTANĀ® prescriptions under TGA Special Access Scheme

Highlights More than 1,000 SPONTAN® prescriptions issued under the TGA Special Access Scheme Growing prescriber network with continued uptake in complex ED cases, including post-prostate cancer patients Real-world insights informing US commercial strategy ahead of ROXUS® launch in H1 CY2026 LTR Pharma Limited (ASX:LTP) (“LTR Pharma” or “the Company”) is pleased to announce that more than 1,000 SPONTAN® prescriptions have now been issued in Australia under the Therapeutic Goods Administration (TGA) Special Access Scheme (SAS Category B). SPONTAN is being prescribed for patients with unmet clinical needs, including men who have not achieved adequate benefit from traditional oral PDE5 inhibitor…

  • Contains:
  • Engineering, Medical Health Aged Care
  • 17/12/2025
  • 09:02
UNSW Sydney

UNSW students claim victory in international artificial heart competition

A team of undergraduate engineering students from UNSW Sydney has claimed first place at a prestigious international artificial heart design competition in Vienna. The…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.